Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SL209
- Development stage
- Phase 3
- Lead developer
- Beijing Pharmaceutical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
SL209 is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist currently under clinical investigation for the treatment of type 2 diabetes mellitus. Developed by Beijing SL Pharmaceutical, the drug functions by activating the GLP-1 receptor, which leads to glucose-dependent insulin secretion, suppression of inappropriate glucagon secretion, and slowing of gastric emptying. These mechanisms work synergistically to lower blood glucose levels and may also contribute to weight loss. As a long-acting formulation, it is designed to provide sustained glycemic control with less frequent dosing compared to short-acting GLP-1 mimetics. The drug is typically administered via subcutaneous injection.
02
Targets
Beyond the preview
Go deeper on SL209.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SL209.